Detailed description page of ThPDB2

This page displays user query in tabular form.

16223 details
Primary information
ID16223
Therapeutic IDTh1736
Protein NameGnRH pharmaccine
SequenceNA
Molecular Weight1212.3143
Chemical FormulaC60H73N15O13
Isoelectric PointNA
HydrophobicityNA
Melting pointNA
Half-lifeNA
DescriptionThe GnRH pharmaccine consists of synthetic peptides (constructed to "look like" GnRH), which are bound chemically to a carrier and suspended in a proprietary "delivery vehicle". The pharmaccine is administered intramuscularly to the patient by injection and induces an immune response or production of antibodies in the patient, which neutralize GnRH thus removing it from circulation.
Indication/DiseaseInvestigated for use/treatment in prostate cancer.
PharmacodynamicsNA
Mechanism of ActionThe immunological neutralization of Gonadotropin Releasing Hormone (GnRH) by the antibodies induced by GnRH pharmaccine shuts down the production of testosterone in the testes. Testosterone fuels prostate cancer, both early stage, primary cancer and metastatic (spreading) cancer. Like physical castration, hormonal, or biological blockage of testosterone has been shown to be efficacious in humans for the treatment of both early and late state prostate cancer. Aphton's GnRH pharmaccine, which is expected to be reversible based on the mechanism of action (in contrast to surgical castration), induces hormonal, or biological blockage of testosterone.
ToxicityNA
MetabolismNA
AbsorptionNA
NA
ClearanceNA
CategoriesNA
Patents NumberNA
Date of IssueNA
Date of ExpiryNA
Drug InteractionNA
TargetNA
Brand NameNA
CompanyNA
Brand DescriptionNA
Prescribed ForNA
Chemical NameNA
FormulationNA
Physical Appearance NA
Route of AdministrationNA
Recommended DosageNA
ContraindicationNA
Side EffectsNA
Useful Link 1Link
Useful Link 2NA
RemarksNA